{"entity":{"id":"avc-203","kind":"drug","name":"AVC-203","aka":["Allo-QuadCAR01-T"],"tldr":"AVC-203 is an experimental allogeneic CRISPR-engineered dual-targeting switchable CAR-T cell therapy from AvenCell Therapeutics, in phase 1 trials for relapsed/refractory B-cell malignancies and diffuse large B-cell lymphoma.","summary":"AVC-203 (Allo-QuadCAR01-T) is an allogeneic CRISPR-engineered dual-targeting switchable CAR-T cell therapy from AvenCell Therapeutics, with AvenCell Europe GmbH as partner. Off-the-shelf donor CAR-T cells, CRISPR-engineered, that target cells expressing CD19 and/or CD20, built on the switchable RevCAR receptor so other targets can be added through bridging proteins. Its furthest stage is phase 1, for relapsed/refractory B-cell malignancies and diffuse large B-cell lymphoma. No clinical trial naming it is registered on ClinicalTrials.gov. First patient dosed in phase 1 QUADvance in April 2026 (company release 2 April 2026); registry phase 1/2 recruiting (NCT07284433). It has not been shown to work in people.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"AvenCell Therapeutics: avencell.com","url":"https://avencell.com/avencell-therapeutics-announces-first-patient-dosed-in-phase-i-quadvance-study-with-avc-203-a-novel-allogeneic-cd19-cd20-dual-targeting-car-t-investigational-therapy-for-the-treatment-of-relapsed-ref/"},{"label":"AvenCell Therapeutics: avencell.com","url":"https://avencell.com/pipeline/"},{"label":"AvenCell Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/study/NCT07284433"}],"tags":["pipeline"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["cd19","cd20"],"drugs":[],"companies":["avencell-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"AVC-203","modality":"Allogeneic CRISPR-engineered dual-targeting switchable CAR-T cell therapy","mechanism":"Off-the-shelf donor CAR-T cells, CRISPR-engineered, that target cells expressing CD19 and/or CD20, built on the switchable RevCAR receptor so other targets can be added through bridging proteins.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/avc-203/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"},{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/"}],"company":[{"id":"avencell-therapeutics","kind":"company","name":"AvenCell Therapeutics","route":"/companies/avencell-therapeutics/"}]}}